Shakespeare Marathon 2026
Run with #TeamRetinaUK at the Shakespeare Marathon 2026, during our special year of 50th anniversary events.
Search
Search results
Taking part in the 2021 Virtual London Marathon
Caryn talks about her experience taking part in the 2021 Virtual London Marathon.
New ‘vision’ and identity sight loss charities
The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
Getting a referral
If you have a diagnosis of an inherited retinal condition, or you are a close relative of somebody living with one of these conditions, you are entitled to access testing and genetic counselling.
Easter Fundraising
If you could use the long bank holiday weekend to fundraise for Retina UK, we would love to hear from you!
Cell-ebrating the dosing of patients with jCell in a phase 2 clinical trial for RP
The latest research news from Retina UK.
Slowing sight loss in stargardts: Ocugen’s gene therapy trial offers promising early results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
Ocugen completes dosing of GARDian3 trial for OCU410ST ahead of schedule
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.